Anavex Life Sciences Corp (AVXL)

[georgejjl]

Two questions for today.

Question 1:

Approximately 24% of Alzheimer's patients also have open-angle glaucoma as a comorbidity.

It has been reported that activation of the sigma 1 receptor appears to be a potentially good target for treating glaucoma. We know that Blarcamesine activates the sigma 1 receptor. Therefore, Blarcamesine may be a potentially good treatment for glaucoma.

Since the Phase 2b/3, Double-Blind, Randomized, Placebo-Controlled 48-week Safety and Efficacy Trial of ANAVEX2-73 for the Treatment of Early Alzheimer's Disease (AD) has 509 participants.

Of the 509 participants approximately 169 of those participants have received the high 50 mg per day dose of Blarcamesine and approximately 169 of theos participants have received the lower 30 mg per day dose.

Are the investigators in the trials looking for positive events in the trial that may be serendipitous such as improvement of vision for participants in the trials?

There is a potential for vision improvement in a fairly high number of trial participants that may also have open-angle glaucoma. Also there may also be serendipitous improvements for other commodities.

Question 2:

For the OLE (open label extension) are all the participants including those previously on placebo going to be slowly titrated up to the maximum 50 mg per day dose or the highest tolerable dose for each individual participant?

Good luck and GOD bless,